Back

Haemodynamic signature of SGLT2 inhibition: greater early NT-proBNP reduction with dapagliflozin versus empagliflozin in patients with atrial fibrillation and heart failure

14 April 2026 (13:30 - 14:15)
Organised by: Logo
Congress Presentation Part of: Heart failure in atrial fibrillation Heart Failure in Atrial Fibrillation EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

5 More presentations in this session

Presentation thumbnail
Left atrial structural and functional assessment by cardiac magnetic resonance in atrial fibrillation-mediated cardiomyopathy
Mr T. Efraimidis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Analysis of guideline-directed medical therapy in patients with reduced ejection fraction undergoing pulsed field ablation for atrial fibrillation: a multicentre study
Doctor S. Aminolsharieh Najafi (Frankfurt am Main, DE)
Abstract Slides Video
Presentation thumbnail
Phenotyping atrial myopathy in HFpEF patients with and without clinical atrial fibrillation
Miss S. Haack (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Atrial fibrillation versus heart failure with preserved ejection fraction as drivers of atrial functional mitral and tricuspid regurgitation: clinical and echocardiographic profiles across phenotypes
Doctor H. Uzun (Izmir, TR)
Abstract Slides Video
Presentation thumbnail
Specific phenotypes impact heart failure (HF) outcomes in atrial fibrillation (AF) with hf with preserved ejection fraction (pEF): can there be a role for "complementary" therapy?
Doctor R. Nagarakanti (Flagstaff, US)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure in atrial fibrillation

The Event

Event poster

EHRA 2026

14 April 2026 13:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources